BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on financial results for the quarter and year ended March 31, 2024.16-05-2024
16-05-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Change in Directorate
The Board has approved the appointment of Mr. Atul Dhawan as an Additional Director (Non Executive and Independent) of the Company w.e.f. May 16, 2024.16-05-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Date of payment of Dividend
Date of payment of dividend16-05-2024
BIOCON LTD. - 532523 - Record Date For Final Dividend
The Company has fixed July 05, 2024 as the record date for determining the entitlement of members to final dividend for FY 31.03.2024.16-05-2024
BIOCON LTD. - 532523 - Corporate Action-Board to consider Dividend
The Board at its Board meeting held on May 16, 2024 has recommended final dividend of 10% i.e. Re. 0.50 per share16-05-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Dividend Updates
The Board recommended a final dividend at the rate of 10% i.e. Re. 0.50 per equity share, subject to the shareholders'' approval.16-05-2024
BIOCON LTD. - 532523 - Outcome Of Board Meeting And Audited Financial Results For The Financial Year Ended 31.03.2024
Outcome of Board meeting and Audited Financials Results for the financial year ended 31.03.202416-05-2024
BIOCON LTD. - 532523 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 16, 2024
Outcome of Board Meeting held on May 16, 202416-05-2024
Biocon To Sell Chronic Weight Management Drug In Mexico
Under the deal with Mexico-based Medix, Biocon will be responsible for obtaining regulatory approval, manufacturing and supply of the drug.13-05-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release13-05-2024